AstraZeneca's Oncology Growth Is Outrunning The Farxiga Decline

AstraZeneca's oncology sales growth outpaced the decline in its diabetes drug, Farxiga, in the third quarter. The company's oncology pipeline continues to perform well, with several recent approvals and positive clinical trial results.

The company also provided an update on its financial performance, with revenue and EPS in line with expectations.